Duke Health: Enzalutamide Helps Extend Life for Men With Advanced Prostate Cancer
May 22, 2025
May 22, 2025
DURHAM, North Carolina, May 22 -- Duke Health issued the following news release:
* * *
Enzalutamide Helps Extend Life for Men with Advanced Prostate Cancer
DURHAM, N.C. - The combination of enzalutamide with androgen deprivation therapy (ADT) significantly increases the chance of five-year survival for men with metastatic hormone-sensitive prostate cancer, according to a five-year follow-up of the global ARCHES study led by the Duke Cancer Institute.
. . .
* * *
Enzalutamide Helps Extend Life for Men with Advanced Prostate Cancer
DURHAM, N.C. - The combination of enzalutamide with androgen deprivation therapy (ADT) significantly increases the chance of five-year survival for men with metastatic hormone-sensitive prostate cancer, according to a five-year follow-up of the global ARCHES study led by the Duke Cancer Institute.
. . .